latest news releases from the newsroom
Epigenomics AG Announces End of VC Pooling
BERLIN and SEATTLE, Nov. 15, 2005 (PRIMEZONE) -- Epigenomics AG (Frankfurt, Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that it has been informed by the majority of its venture capital investors:
Skandia's Nominating Committee
STOCKHOLM, Sweden, Nov. 15, 2005 (PRIMEZONE) -- The following persons have now been appointed to serve on the nominating committee ahead of the 2006 Annual General Meeting:
Trintech Group Plc
Trintech to Unveil New Pay-at-Pump System at Cartes 2005
DUBLIN, Ireland, Nov. 15, 2005 (PRIMEZONE) -- Cartes 2005 at Paris, France -- Trintech Group Plc (Nasdaq:TTPA), a leading provider of transaction reconciliation and payment infrastructure solutions, will unveil its latest unattended payment terminal at the Cartes 2005 Exposition in Paris, France. The OpenPay UPT 4000 is targeted at petrol stations, convenience stores and supermarkets that need a compact, powerful pay-at-pump terminal that is compliant with the latest terminal security standards and technologies. Trintech's primary route to market for this product will be through channel partners including pump manufacturers, forecourt Point-of-Sale suppliers and retail system integrators.
Antisoma's AS1404 Whips Up a Cytokine Storm to Attack Cancer
LONDON and PHILADELPHIA, Nov. 15, 2005 (PRIMEZONE) -- A presentation today at the AACR-NCI-EORTC meeting in Philadelphia offers new insights into the mechanism of action of Antisoma's phase II cancer drug AS1404. Researchers at the Division of Basic Medical Sciences at St George's, University of London have shown that the drug increases levels of various cytokines, biological mediators with profound effects on tumours and the body's response to cancer. These include tumour necrosis factor (TNF), a cytokine already implicated in the drug's action, as well as other mediators not previously associated with AS1404. Examples are RANTES, MCP-1 and GM-CSF, which stimulate the migration of immune cells called monocytes into tumours, and IL-1ss, which like TNF causes 'haemorrhagic necrosis.' This effect -- the death of tumour cells associated with destruction of their blood supply -- is one of the hallmarks of vascular disrupting agents, the class of drugs to which AS1404 belongs.